No Data
US Stock MarketDetailed Quotes
CTSO Cytosorbents
Watchlist
1.240
-0.010-0.80% Trading 12/06 12:26 ET
1.290High1.220Low10.51KVolume
1.290Open1.250Pre Close13.19KTurnover0.03%Turnover RatioLossP/E (TTM)55.10MMarket Cap4.59052wk HighLossP/E (Static)44.44MShares1.03052wk Low2.97P/B46.30MFloat Cap98.750Historical High--Dividend TTM37.34MShs Float0.750Historical Low--Div YieldTTM5.60%Amplitude1.255Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Cytosorbents Company
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Princeton, NJ.
Revenue Breakdown
Business
Currency:USD
2022/12/31
Stock NameRevenueRatio
CytoSorb sales28.57M82.37%
Grant income5.33M15.36%
Other sales787.2K2.27%
News
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersCytoSorbents (NASDAQ:CTSO) stock rose 17.3% to $1.29 during Friday's pre-market session. The company's market cap stands at $57.3 million. Tonix Pharmaceuticals (NASDAQ:TNXP) stock rose 15.43%
Promising Financial Outlook and Potential Game-Changer Study Drive Buy Rating for Cytosorbents
Cytosorbents GAAP EPS of -$0.21 Misses by $0.09, Revenue of $8.8M Misses by $0.52M
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Rockhoundj : I can’t buy what I can’t pronounce
Rockhoundj : Sssss
Say it with me
AmyNicOP Rockhoundj: Sigh-toe-sore-bents
AmyNicOP Rockhoundj:
PYUN970IHaveChosen :
